The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Anavex Life Sciences (NASDAQ:AVXL) traded ~10% higher in the premarket after the company said it submitted a marketing ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

The surprising failure of ABBV’s Emraclidine in its EMPOWER trials significantly reduces competition in the muscarinic space, offering a potential advantage for Neurocrine if it can successfully ...